Novartis is making a strategic move by signing a deal with Abogen Biosciences for an early-stage experimental treatment for autoimmune diseases. The agreement includes an upfront payment of $575 million for global rights to Abogen's messenger RNA therapy, with potential milestone payments totaling $7.2 billion.
This partnership reflects the increasing interest of Western pharmaceutical companies in China's biotech sector, especially as Novartis faces challenges from recent clinical trial setbacks and the looming patent cliff expected in the early 2030s. The deal is part of a larger trend, as other companies like Novo and GSK are also pursuing similar agreements to bolster their drug pipelines.
Analysts from ING predict that by 2026, China will contribute to a significant portion of new drug molecules globally, indicating a shift in the pharmaceutical landscape towards Chinese biotech innovations